Corcept Announces FDA Approval of Lifyorli for Ovarian Cancer and Q1 2026 Financial Results
On April 30, 2026, Corcept Therapeutics reported financial results for the first quarter of 2026 and provided a major regulatory update. The company announced that the FDA approved Lifyorli (relacorilant) in March 2026 for the treatment of platinum-resistant ovarian cancer, more than three months ahead of its PDUFA date. Following the approval, the regimen was added to the NCCN Guidelines as a preferred treatment. Financially, Corcept reported Q1 revenue of $164.9 million, a slight increase year-over-year, but recorded a net loss of $31.8 million due to increased spending for the Lifyorli launch. Despite the loss, the company raised its 2026 revenue guidance to $950 million β $1.05 billion and expects to return to profitability in Q2 2026. Clinical updates include expected results from the Phase 2 BELLA trial (ovarian cancer) and Phase 2b MONARCH trial (MASH) by the end of 2024, and plans to initiate a Phase 3 trial of dazucorilant in ALS later this year. The company is also engaging with the FDA regarding a New Drug Application for relacorilant in Cushingβs syndrome.